NanoViricides, Inc.
NNVC
Last
$1.30
Day
-0.8%
1y
-8.1%
5y
-67.9%
52w
-41.3%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1333d
EMA 21
1.35
EMA 50
1.35
EMA 200
1.34
20d high
-26.4%
5y high
-76.4%
5y range
10th
Positions held
Your positionsNNVC isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
13
Hold
watch
Signal
Neutral
Target
$1.56
Stop
$1.10
Stop distance
15.4%
Target vs last
+20.0%
Fundamentals
| Market cap | $33.44M | Enterprise value | $30.64M | Trailing P/E | — | Forward P/E | -3.74 |
| PEG | — | Price / book | 3.10 | Beta | 1.79 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -101.5% | ROA | -55.5% | Debt / equity | — |
| Current ratio | 2.66 | Free cash flow | -$4.75M | Analyst recommendation | strong_buy | Mean target | $6.00 |
| 52w high | $2.23 | 52w low | $0.85 |
Quarterly
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$2.0M | -$2.2M | -$1.8M | -$2.1M | -$2.2M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$2.0M | -$2.2M | -$1.8M | -$2.1M | -$2.2M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$9.5M | -$8.3M | -$8.6M | -$8.1M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$9.6M | -$8.5M | -$8.9M | -$8.1M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
2026-09-29 · NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
2026-09-28 · NanoViricides: Fiscal Q4 Earnings Snapshot
2026-09-23 · Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
2026-09-17 · These Biotech Stocks Are Cheap Based On 1 Fundamental Measure
Price (daily)
Full chart · RSI · MACD · patternsNNVC · daily-14.4% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin